In our study, polypharmacy was present in the RA and PsA patients both at the time of diagnosis and during the treatment process, and the presence of baseline polypharmacy was among the factors that affected the treatment of these patients by significantly affecting their 6th-month DAS-28 CRP values. Here, CRP is linked to rheumatoid arthritis.